[go: up one dir, main page]

DK1608634T3 - Fremgangsmåder til isolering af krystallinsk form af 5-azacytidin - Google Patents

Fremgangsmåder til isolering af krystallinsk form af 5-azacytidin

Info

Publication number
DK1608634T3
DK1608634T3 DK04721078.6T DK04721078T DK1608634T3 DK 1608634 T3 DK1608634 T3 DK 1608634T3 DK 04721078 T DK04721078 T DK 04721078T DK 1608634 T3 DK1608634 T3 DK 1608634T3
Authority
DK
Denmark
Prior art keywords
azacytidine
procedures
insulating
crystallinic
crystallinic form
Prior art date
Application number
DK04721078.6T
Other languages
English (en)
Inventor
Lee Alani Selvey
Dumitru Ionescu
Peter Blumbergs
Original Assignee
Celgene Internat Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1608634(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Internat Sarl filed Critical Celgene Internat Sarl
Application granted granted Critical
Publication of DK1608634T3 publication Critical patent/DK1608634T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK04721078.6T 2003-03-17 2004-03-16 Fremgangsmåder til isolering af krystallinsk form af 5-azacytidin DK1608634T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/390,530 US6943249B2 (en) 2003-03-17 2003-03-17 Methods for isolating crystalline Form I of 5-azacytidine
PCT/US2004/007896 WO2004082822A2 (en) 2003-03-17 2004-03-16 Methods for isolating crystalline form i of 5-azacytidine

Publications (1)

Publication Number Publication Date
DK1608634T3 true DK1608634T3 (da) 2013-08-12

Family

ID=32987551

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10151392.7T DK2181988T3 (da) 2003-03-17 2004-03-16 Farmaceutiske sammensætninger baseret på krystallinsk form i af 5-azacytidin
DK04721078.6T DK1608634T3 (da) 2003-03-17 2004-03-16 Fremgangsmåder til isolering af krystallinsk form af 5-azacytidin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10151392.7T DK2181988T3 (da) 2003-03-17 2004-03-16 Farmaceutiske sammensætninger baseret på krystallinsk form i af 5-azacytidin

Country Status (16)

Country Link
US (5) US6943249B2 (da)
EP (3) EP2181988B1 (da)
JP (1) JP4792550B2 (da)
AU (2) AU2004222274B2 (da)
BR (1) BRPI0408506A (da)
CA (1) CA2518973A1 (da)
CY (2) CY1114213T1 (da)
DK (2) DK2181988T3 (da)
EC (1) ECSP056023A (da)
ES (2) ES2575535T3 (da)
HU (1) HUE028268T2 (da)
MX (1) MXPA05009969A (da)
PL (2) PL1608634T3 (da)
PT (2) PT1608634E (da)
SI (2) SI2181988T1 (da)
WO (1) WO2004082822A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8902490A (nl) * 1989-10-06 1991-05-01 Leonardus Mathijs Marie Nevels Werkwijze voor het reinigen van rookgassen.
ATE314768T1 (de) * 2001-10-08 2006-01-15 Cit Alcatel Verfahren zur lastverteilung zwischen mehreren gemeinsamen betriebsmitteln in einem kommunikationsnetzwerk und netzwerk zur anwendung des verfahrens
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US7759481B2 (en) * 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
EP2176279A4 (en) * 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
JP2010540556A (ja) * 2007-09-26 2010-12-24 マウント サイナイ スクール オブ メディシン アザシチジン類似体およびその使用
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
US8846628B2 (en) 2008-05-15 2014-09-30 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2010014883A2 (en) 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
AR073003A1 (es) * 2008-08-08 2010-10-06 Scinopharm Taiwan Ltd Proceso para preparar 5-azacitosina nucleosidos y sus derivados
AR076418A1 (es) * 2009-04-27 2011-06-08 Reddys Lab Inc Dr Preparacion de decitabina
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
KR20140019820A (ko) 2011-03-31 2014-02-17 셀진 인터내셔널 에스에이알엘 5-아자시티딘의 합성
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
AU2012312308B2 (en) 2011-09-23 2015-11-19 Celgene Corporation Romidepsin and 5-azacitidine for use in treating lymphoma
CN104039330A (zh) 2011-09-26 2014-09-10 细胞基因公司 化疗耐药性的癌症的联合治疗
JP6231988B2 (ja) 2011-11-03 2017-11-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与
WO2013080221A2 (en) * 2011-12-01 2013-06-06 Hetero Research Foundation Process for alvimopan
US9669048B2 (en) * 2012-10-25 2017-06-06 Fresenius Kabi Oncology Limited Stable pharmaceutical composition of 5-aza-2′-deoxycitidine
US9765108B2 (en) 2012-11-19 2017-09-19 Shilpa Medicare Limited Formulation of 5-azacytidine
WO2014076616A2 (en) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine
US9968627B2 (en) 2013-03-26 2018-05-15 Celgene Corporation Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
CN103450303A (zh) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
LT3182996T (lt) 2014-08-22 2023-03-10 Celgene Corporation Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais
US20160095925A1 (en) * 2014-10-01 2016-04-07 Cadila Healthcare Limited Stable formulation of azacitidine or salts thereof and their process for preparation
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
SG10201912869WA (en) 2015-10-15 2020-02-27 Celgene Corp Combination therapy for treating malignancies
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
CN109988207B (zh) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 阿扎胞苷晶型的制备方法
CN112367971A (zh) 2018-06-11 2021-02-12 加利福尼亚大学董事会 用以治疗眼睛疾病的脱甲基化
CN110642901A (zh) * 2019-11-11 2020-01-03 扬子江药业集团有限公司 阿扎胞苷甲醇化物及其制备方法和药物组合物、用途
US20240262857A1 (en) * 2021-05-27 2024-08-08 Emory University Novel universal anti-rna virus agents

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (da) * 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) * 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) * 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) * 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
JP2002503212A (ja) * 1996-10-16 2002-01-29 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 単環式ヌクレオシド、その類似体および使用
ATE263767T1 (de) * 1999-06-03 2004-04-15 Eisai Co Ltd Kristalline cabapenemderivate und pharmazeutische zubereitungen zur injektion
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
AU2001284469A1 (en) * 2000-09-07 2002-03-22 Kaneka Corporation Methods for crystallization of hydroxycarboxylic acids
JP5105689B2 (ja) * 2001-03-01 2012-12-26 ギリード・サイエンシズ・インコーポレーテッド 多形型および他の結晶型のシス−ｆｔｃ
EP1545558A4 (en) * 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2503150A1 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
EP1517893A2 (en) 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6877855B2 (en) 2003-07-08 2005-04-12 Dave Ng Spectacles with peripheral lens support
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
WO2008028193A2 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) * 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008092127A1 (en) * 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
EP2048151A1 (en) * 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
US20100311683A1 (en) * 2007-11-01 2010-12-09 Beach C L Cytidine analogs for treatment of myelodysplastic syndromes
US8846628B2 (en) * 2008-05-15 2014-09-30 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2010014883A2 (en) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2520581A1 (en) * 2008-08-06 2012-11-07 Sicor, Inc. Method for the determination the purity of 5-Azacytidine
AR073003A1 (es) * 2008-08-08 2010-10-06 Scinopharm Taiwan Ltd Proceso para preparar 5-azacitosina nucleosidos y sus derivados
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) * 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina

Also Published As

Publication number Publication date
US20130274459A1 (en) 2013-10-17
US20100292180A1 (en) 2010-11-18
US20120245342A1 (en) 2012-09-27
US8211862B2 (en) 2012-07-03
US8975392B2 (en) 2015-03-10
CY1114213T1 (el) 2016-08-31
ES2575535T3 (es) 2016-06-29
EP1608634A4 (en) 2006-03-15
WO2004082822A3 (en) 2005-07-07
US20040186284A1 (en) 2004-09-23
US6943249B2 (en) 2005-09-13
EP2266965A1 (en) 2010-12-29
US7700770B2 (en) 2010-04-20
PL1608634T3 (pl) 2013-10-31
CY1117639T1 (el) 2017-04-26
DK2181988T3 (da) 2016-06-06
US8481715B2 (en) 2013-07-09
PT1608634E (pt) 2013-08-27
CA2518973A1 (en) 2004-09-30
SI2181988T1 (sl) 2016-09-30
PL2181988T3 (pl) 2016-11-30
BRPI0408506A (pt) 2006-03-14
ECSP056023A (es) 2006-01-27
SI1608634T1 (sl) 2013-09-30
AU2010241198B2 (en) 2012-05-10
AU2004222274B2 (en) 2010-11-04
EP1608634B1 (en) 2013-05-22
JP2006523210A (ja) 2006-10-12
WO2004082822A2 (en) 2004-09-30
JP4792550B2 (ja) 2011-10-12
EP2181988B1 (en) 2016-05-11
US20050272675A1 (en) 2005-12-08
AU2010241198A1 (en) 2010-11-25
MXPA05009969A (es) 2006-02-17
EP2181988A1 (en) 2010-05-05
EP1608634A2 (en) 2005-12-28
ES2425474T3 (es) 2013-10-15
AU2004222274A1 (en) 2004-09-30
HUE028268T2 (en) 2016-12-28
PT2181988E (pt) 2016-06-15

Similar Documents

Publication Publication Date Title
DK1608634T3 (da) Fremgangsmåder til isolering af krystallinsk form af 5-azacytidin
DK3395338T3 (da) Hurtigt opløsende formulering af cinacalcet-hcl
DK1575416T3 (da) Fremgangsmåder til diagnosticering af præeklampsi
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1763673T3 (da) Anvendelser af gelformuleringer
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
DK1687066T3 (da) Fremgangsmåder til immunmodulering
DK1348473T3 (da) Elementsæt til samling af strukturer
DK2377931T3 (da) Varianter af glycosidhydrolase
DK1680561T3 (da) Isolationselement af mineralfibre til skibsbygning
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
EP1660436A4 (en) cathepsin inhibitors
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
DK1744866T3 (da) Fremgangsmåde til at vælge formuleringer til behandling af elektriske kabler
EP1608385A4 (en) THERAPEUTIC COMPOSITIONS
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
EP1797691A4 (en) BLOCK MODULATION
DK1825484T3 (da) Fremgangsmåde til fremstilling af kabler
NO20043305D0 (no) Preparation of lodixanol
DK1773787T3 (da) Fremgangsmåde til fremstilling af 3-phenyl(thio)uraciler og -dithiouraciler
DK1337228T3 (da) Sammensætninger til fjernelse af human cerumen
DK1575941T3 (da) Fremgangsmåde til fremstilling af (S)-pantoprazol
EP1667973A4 (en) QUINOLINE POTASSIUM CHANNEL INHIBITORS
IS8399A (is) Form fjölgervings 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólíns
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose